Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study

Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study

Pivotal trials showed the effectiveness of the monoclonal antibody ocrelizumab in relapsing and progressive multiple sclerosis (MS). However, data on everyday practice in MS patients and markers of treatment effectiveness are scarce. We aimed to collect real-world data from ocrelizumab-treated MS pa...

Full description

Bibliographic Details
Main Authors: Roberta Lanzillo, Antonio Carotenuto, Elisabetta Signoriello, Rosa Iodice, Giuseppina Miele, Alvino Bisecco, Giorgia Teresa Maniscalco, Leonardo Sinisi, Felice Romano, Maria Di Gregorio, Luigi Lavorgna, Francesca Trojsi, Marcello Moccia, Mario Fratta, Nicola Capasso, Raffaele Dubbioso, Maria Petracca, Antonio Luca Spiezia, Antonio Gallo, Martina Petruzzo, Marcello De Angelis, Simona Bonavita, Giacomo Lus, Gioacchino Tedeschi, Vincenzo Brescia Morra
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Journal of Clinical Medicine
Subjects:
progression
multiple sclerosis
ocrelizumab
disease-modifying treatment
real-world
Online Access:https://www.mdpi.com/2077-0383/11/8/2081

Internet

https://www.mdpi.com/2077-0383/11/8/2081

Similar Items